Patents by Inventor John Richard Puddefoot

John Richard Puddefoot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions
    Patent number: 9422369
    Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: August 23, 2016
    Assignee: Queen Mary & Westfield College
    Inventors: Gavin Paul Vinson, Stewart Barker, John Richard Puddefoot
  • Synthetic scFv Analogue To The 6313/G2 (Anti Angiotensin II Type 1 Receptor) Monoclonal Antibody Variable Regions
    Publication number: 20140127205
    Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1 is GYSFTGYNMN VHCDR2 is NIDPYYGGTTYNQKFKG VHCDR3 is EVDY VLCDR1 is RASKSVSTSTSGYSYMH VLCDR2 is LVSNLES VLCDR3 is QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.
    Type: Application
    Filed: June 20, 2013
    Publication date: May 8, 2014
    Applicant: Queen Mary & Westfield College
    Inventors: Gavin Paul Vinson, Stewart Barker, John Richard Puddefoot
  • Therapeutic Uses of Monoclonal Antibodies to the Angiotensin-II Type-1 Receptor
    Publication number: 20130202604
    Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence (SEQ?ID?NO:?1) MILNSSTEDG?IKRIQDDCPK?AGRHNYIFVM?IPTLYSIIFV?VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.
    Type: Application
    Filed: January 24, 2013
    Publication date: August 8, 2013
    Applicants: Queen Mary & Westfield College, University of London
    Inventors: Queen Mary & Westfield College, University of London, Gavin Paul Vinson, John Richard Puddefoot
  • Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions
    Patent number: 8487082
    Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1?is?GYSFTGYNMN VHCDR2?is?NIDPYYGGTTYNQKFKG VHCDR3?is?EVDY VLCDR1?is?RASKSVSTSTSGYSYMH VLCDR2?is?LVSNLES VLCDR3?is?QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: July 16, 2013
    Assignee: Queen Mary & Westfield College
    Inventors: Gavin Paul Vinson, Stewart Barker, John Richard Puddefoot
  • Therapeutic uses of monoclonal antibodies to the angiotensin-II type 1 receptor
    Patent number: 8383108
    Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGHRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: February 26, 2013
    Assignee: Queen Mary & Westfield College, University of London
    Inventors: Gavin Paul Vinson, John Richard Puddefoot, Stewart Barker
  • Therapeutic Uses Of Monoclonal Antibodies To The Angiotensin-II Type 1 Receptor
    Publication number: 20110256139
    Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGHRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.
    Type: Application
    Filed: April 15, 2011
    Publication date: October 20, 2011
    Inventors: Stewart Barker, John Richard Puddefoot, Gavin Paul Vinson
  • Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
    Patent number: 7951904
    Abstract: The use of monoclonal antibodies to the angiotensin-II type-I receptor is provided for the treatment of cancer and vascular smooth muscle cell proliferation. Specifically, use is provided of a monoclonal antibody or a fragment thereof to a peptide comprising the N-terminal portion of the angiotensin-II type-1 receptor defined by the sequence MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFG in the preparation of a medicament for the treatment of cancer or in the preparation of a medicament for the treatment of vascular smooth muscle (VSM) cell proliferation.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: May 31, 2011
    Assignee: Queen Mary & Westfield College
    Inventors: Stewart Barker, John Richard Puddefoot, Gavin Paul Vinson
  • Synthetic scFv Analogue To The 6313/G2 (Anti Angiotensin II Type 1 Receptor) Monoclonal Antibody Variable Regions
    Publication number: 20110081350
    Abstract: The present invention provides a specific binding molecule which specifically binds to a peptide having the amino acid sequence of EDGIKRIQDD and comprises a polypeptide having an immunoglobulin VL domain linked to an immunoglobulin VH domain in which the VL domain comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2 and VLCDR3, and in which the VH domain comprises Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2, VHCDR3, each having a respective amino acid sequence as follows in which VHCDR1?is?GYSFTGYNMN VHCDR2?is?NIDPYYGGTTYNQKFKG VHCDR3?is?EVDY VLCDR1?is?RASKSVSTSTSGYSYMH VLCDR2?is?LVSNLES VLCDR3?is?QHIRELTRSEG or an amino acid sequence at least 70% identical thereto.
    Type: Application
    Filed: February 18, 2009
    Publication date: April 7, 2011
    Applicant: QUEEN MARY & WESTFIELD COLLEGE
    Inventors: Gavin Paul Vinson, Stewart Barker, John Richard Puddefoot
  • Cancer treatment
    Patent number: 6852316
    Abstract: The present invention relates to the use of angiotensin in a method for the treatment or prevention of cancer. The method comprises administering to a patient in need of treatment an effective amount of an angiotensin.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: February 8, 2005
    Assignee: Queen Mary & Westfield College
    Inventors: Gavin Paul Vinson, John Richard Puddefoot, Miles Gordon Berry
  • Cancer treatment
    Publication number: 20020119142
    Abstract: The present invention relates to the use of angiotensin in a method for the treatment or prevention of cancer. The method comprises administering to a patient in need of treatment an effective amount of an angiotensin.
    Type: Application
    Filed: February 16, 2001
    Publication date: August 29, 2002
    Applicant: Queen Mary & Westfield College [GB/GB]
    Inventors: Gavin Paul Vinson, John Richard Puddefoot, Miles Gordon Berry